赛升药业：控股股东、实控人的一致行动人拟减持不超2%公司股份

Core Viewpoint - The announcement from Sai Sheng Pharmaceutical indicates that major shareholders plan to reduce their holdings, which may impact the stock's performance and investor sentiment [1] Shareholder Information - Shareholder Ma Li holds 29.8468 million shares, representing 6.2% of the company [1] - Shareholder Liu Shuqin holds 8.748 million shares, representing 1.82% of the company [1] - Both shareholders are aligned with the company's controlling shareholder, Ma Biao [1] Reduction Plan - The shareholders plan to reduce their holdings by a total of up to 9.6333 million shares, which is not more than 2% of the total shares [1]